A novel 3-alkenylindol-2-one derivative selectively inhibits the growth of acute myeloid leukemia via modulation of the MYC-PRMT pathway
- 4 July 2025
- journal article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 240, 117111
Abstract
No abstract availableKeywords
Funding Information
- Lanzhou University
- Gansu Provincial Natural Science Foundation (23JRRA1050)
This publication has 42 references indexed in Scilit:
- Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)Current Oncology Reports, 2024
- Protein arginine methyltransferases (PRMTs): Orchestrators of cancer pathogenesis, immunotherapy dynamics, and drug resistanceBiochemical Pharmacology, 2024
- PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemiaMolecular Carcinogenesis, 2023
- Metabolomics study of ribavirin in the treatment of orthotopic lung cancer based on UPLC-Q-TOF/MSChemico-Biological Interactions, 2022
- Downregulation of PRMT5 by AMI-1 enhances therapeutic efficacy of compound kushen injection in lung carcinoma in vitro and in vivoMolecular and Cellular Biochemistry, 2022
- Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CMLCell Metabolism, 2022
- Myelocytomatosis‐Protein Arginine N‐Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular CarcinomaHepatology, 2021
- Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitorsEuropean Journal of Medicinal Chemistry, 2020
- M-TAP Dance: Targeting PRMT1 and PRMT5 Family Members to Push Cancer Cells Over the EdgeCancer Cell, 2019
- Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP LossCancer Cell, 2019